Humana (NYSE:HUM) Price Target Raised to $484.00

Humana (NYSE:HUM) had its target price raised by JPMorgan Chase & Co. from $393.00 to $484.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “neutral” rating on the insurance provider’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 10.83% from the company’s current price.

HUM has been the topic of several other research reports. Wall Street Zen upgraded shares of Humana from a “hold” rating to a “buy” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft started coverage on shares of Humana in a report on Thursday, July 30th. They set a “hold” rating on the stock. Cantor Fitzgerald raised their price objective on shares of Humana from $460.00 to $495.00 and gave the company an “overweight” rating in a research report on Monday. Raymond James Financial reaffirmed an “outperform” rating on shares of Humana in a research note on Friday. Finally, Oppenheimer upped their target price on shares of Humana from $475.00 to $525.00 and gave the stock an “outperform” rating in a research report on Monday, October 12th. Twenty-one equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Humana has an average rating of “Moderate Buy” and an average target price of $469.57.

Humana Price Performance

NYSE HUM traded up $13.49 during trading hours on Tuesday, reaching $436.71. 256,705 shares of the company’s stock were exchanged, compared to its average volume of 1,639,441. The stock has a market cap of $52.44 billion, a PE ratio of 42.42, a price-to-earnings-growth ratio of 2.57 and a beta of 0.65. Humana has a one year low of $163.11 and a one year high of $456.50. The firm has a fifty day moving average of $404.69 and a 200-day moving average of $313.04. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62.

Humana (NYSE:HUM) last released its quarterly earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.30. Humana had a return on equity of 11.20% and a net margin of 0.88%. The firm had revenue of $41.16 billion during the quarter, compared to analysts’ expectations of $40.87 billion. During the same period last year, the firm posted $3.24 EPS. The business’s revenue was up 26.1% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.500- EPS. On average, equities research analysts predict that Humana will post 9.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humana

Hedge funds have recently added to or reduced their stakes in the company. Pinnacle Wealth Planning Services Inc. grew its stake in Humana by 21.8% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 151 shares of the insurance provider’s stock valued at $58,000 after acquiring an additional 27 shares during the period. Wilkerson Advisory Group LLC increased its holdings in shares of Humana by 24.6% during the second quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider’s stock valued at $66,000 after acquiring an additional 33 shares in the last quarter. Moors & Cabot Inc. raised its position in shares of Humana by 4.3% during the third quarter. Moors & Cabot Inc. now owns 804 shares of the insurance provider’s stock worth $307,000 after purchasing an additional 33 shares during the period. Cidel Asset Management Inc. raised its position in shares of Humana by 1.1% during the second quarter. Cidel Asset Management Inc. now owns 3,883 shares of the insurance provider’s stock worth $1,542,000 after purchasing an additional 41 shares during the period. Finally, Greenleaf Trust lifted its holdings in shares of Humana by 1.7% in the 3rd quarter. Greenleaf Trust now owns 2,524 shares of the insurance provider’s stock worth $963,000 after purchasing an additional 41 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Key Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Humana reported a narrower Q3 loss and revenue above analyst expectations, then raised its 2026 adjusted EPS guidance. The company cited easing medical costs, supporting expectations for improved profitability. Humana lifts annual profit forecast as medical costs ease
• Positive Sentiment: Analysts raised their price targets after the results: Barclays to $587, Guggenheim to $521 and Cantor Fitzgerald to $495, with each maintaining a bullish rating. Guggenheim has also issued a positive forecast for HUM. Humana Analysts Raise Their Forecasts After Q3 Results Guggenheim Issues Positive Forecast for Humana Stock Price
• Positive Sentiment: A reported rebound in Humana’s Medicare Advantage star ratings could unlock as much as $4.8 billion, potentially supporting future revenue. The article also flags a cost to brokers, tempering the opportunity. Humana’s stars rebound could unlock $4.8bn, but brokers paid a price
• Neutral Sentiment: Humana commenced cash tender offers for eight series of senior notes. The offers involve repurchasing outstanding debt; the announcement provided no immediate change to the company’s earnings outlook. Humana Commences Offers to Purchase for Cash Certain Outstanding Debt Securities

About Humana

Humana Inc is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans.

The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

Humana was founded in 1961 as a nursing home company and later expanded into health insurance.